Patients experiencing inadequate appetite suppression after reaching maintenance doses should consult their healthcare provider for comprehensive evaluation
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-833-934-6891 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Semaglutide is FDA-approved for type 2 diabetes management (Ozempic, Rybelsus), cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease (Ozempic), chronic weight management in obesity or overweight with comorbidities (Wegovy), and cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight (Wegovy)
Please check with your State's Medicaid program to determine coverage
STEP 5 Two-Year Safety Results In the STEP 5 trial involving 304 participants (152 receiving semaglutide, 152 receiving placebo), gastrointestinal adverse events occurred in 82.2% of the semaglutide group versus 53.9% of the placebo group over the two-year period
Vitamin D and the immune system
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
